DexCom, Inc. (DC4.F)

107,22 +0,58 (+0,54%) Ab 08:20AM CEST. Markt geöffnet.

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 9.500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President	2,99M	N/A	1958
Mr. Jereme M. Sylvain	Executive VP, CFO & Chief Accounting Officer	1,04M	N/A	1980
Mr. Jacob Steven Leach	Executive VP & COO	1,19M	N/A	1978
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer	1,13M	N/A	1970
Ms. Teri Lawver	Executive VP & Chief Commercial Officer	1,31M	N/A	1967
Mr. Girish Naganathan	Executive VP & CTO	392,34k	N/A	1977
Stacey Stewart	Senior VP & Chief Information Officer	N/A	N/A	N/A
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	N/A	N/A	N/A
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs	N/A	N/A	1981
Ms. Leverne Marsh	Executive Vice President of Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 4. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 6, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.